Anti-ulcer activity and other pharmacological properties of lozilurea.
As a result of trials on a large series of compounds, one of these, N' -3-chlorobenzyl-N'-ethylurea (lozilurea, ITA 312) has shown marked anti-ulcer activity. It has shown itself to be active against chemically and neurogenically induced gastric and duodenal lesions in various experimental animal models. It has no major anti-secretory action. The experimental data obtained suggest that the mechanism of action of lozilurea consists in increasing the protective function of the mucus barrier. In the screening trials carried out in order to detect the side effects of lozilurea, it has shown sedative, antipyretic and vasodilatory actions.
D000818:Animals; D000897:Anti-Ulcer Agents / Q000633:toxicity; D001241:Aspirin / Q000633:toxicity; D004285:Dogs; D004381:Duodenal Ulcer / Q000188:drug therapy; D005260:Female; D005753:Gastric Mucosa / Q000187:drug effects; D006168:Guinea Pigs; D006595:Hexosamines / Q000378:metabolism; D066298:In Vitro Techniques; D007213:Indomethacin / Q000633:toxicity; D008297:Male; D051379:Mice; D009088:Mucoproteins / Q000378:metabolism; D011506:Proteins / Q000378:metabolism; D011619:Psychotropic Drugs; D051381:Rats; D011919:Rats, Inbred Strains; D013276:Stomach Ulcer / Q000139:chemically induced; D014508:Urea / Q000031:analogs & derivatives* / Q000494:pharmacology / Q000633:toxicity
D000897:Anti-Ulcer Agents; D006595:Hexosamines; D009088:Mucoproteins; D011506:Proteins; D011619:Psychotropic Drugs; C040094:lozilurea; D014508:Urea; D001241:Aspirin; D007213:Indomethacin